您的浏览器禁用了JavaScript(一种计算机语言,用以实现您与网页的交互),请解除该禁用,或者联系我们。 [招银国际]:美国17亿美元回购带来积极惊喜;提升目标价至112港元 - 发现报告

美国17亿美元回购带来积极惊喜;提升目标价至112港元

2026-03-23 Nika Ma 招银国际 陈曦
报告封面

AIA Group Ltd. (1299 HK)AIA Group Ltd. (1299 HK)-$1.7bn buyback a +VE surprise;lift TP to HK$112 US$1.7bn buyback a+VE surprise;lift TP to AIAdeliveredbroadly in-line FY25results withVONBgrowing 15% CER (or 17% AER)to US$5,516mn, while the new US$1.7bn share buybackfor FY26was a positivesurprisein addition to US$2.6bn total dividends (+10% YoY). 4Q VONB moderated toUS$1.2bn, up 9.7% YoY, slower than a 27% rise in 3Q25 (US$1.48bn). Margin sawabroad-based expansion except in SG (-3.4pct), at 58.5% in the Group level, up 3.6pctYoY, a slight beatvsour estimate (Table), thanks to a favourable product mix in HK(+3.0pct) and TH (+11.4pct) alongside the repricing benefit from mainland Chinamarket in 3Q25 (+1.4pct). Group OPAT grew 8% CER (or 7% AER) to US$7.14bn,translating to +12% per-share growth, tracking the 9%-11% OPAT per-share CAGRtarget in 2023-2026. Operating RoEV and ROE reached 15.8%/15.5% by year-end, up0.9pct/ 0.7pct YoY, both at annual highs. USFG remained strong at US$6.8bn, up 11%YoYonper share basis, and net FSG, the key metric for shareholder returns, stoodabove US$4.4bn, up 9%/14% per shareYoY. Driven by resilient organic growth andprudent capital management, the insurer deliveredUS$4.7bn total shareholder returnin FY25 throughUS$2.4bn dividends and US$2.3bn buyback.AIA China’s VONBgrowth edged up above 20% YoY in Jan-Feb 2026, while we believe momentum in AIAThailand could moderate in 1Q26E given a high base from the front-loaded sales Target PriceHK$112.00(Previous TPHK$89.00)Up/DownsideCurrent PriceHK$86.05 InsuranceNika MA(852) 3900 0805nikama@cmbi.com.hk VONB remained broadly on track.InFY25, Group VONBrose15% (CER) YoYto US$5.52bn, tracking Bloomberg consensus of US$5.54bn. 4Q VONB moderatedto US$1.2bn (+9.7%), slower than a 27% rise in 3Q, while margin peaked at 60.7%,up2.5pct/1.8pct QoQ/YoY.The4Qslowdown could be attributable to TH andmainland China, given 1) substantial medical insurance sales in 4Q24 prior to theco-payment rules implementation and 2)early preparation for 1Q26 jumpstart salesfor AIA China.Agency(73% mix) and partnership (27% mix)VONBrose 13%/22%YoY toUS$4.3bn/1.6bn.Marginticked up3.6pct YoY to 58.5% in FY25,thanks to Geographic dynamics:HKremained thestar VONB contributor; AIA Chinaeased pressure of economic assumption change; THreleasednew GrowthStrategy.HK VONB grew 28%YoY to US$2.26bn (39% mix) in FY25,reflectingsustained momentum into 2H with VONB up 32% YoY (1H25: +24%). Marginexpanded 3pct YoY to 68.5% in FY25, thanks to the new flagship product launch.AIA TH saw 13% YoY VONB growth to US$993mn(17% mix),with margin up11.4pct YoY to 110.9%.AIA ChinaVONBrose 2%YoY toUS$1.24bnin FY25(21%mix),primarilydue to the economic assumption change in 1H25(-4% YoY),butrebounded in 2H with VONB up by 14% YoY. Thisstrongmomentum sustained inJan-Feb 2026 with VONB up >20% YoY as reported. China Growth Strategyprogressed on track with the nine new regions’ VONBaccelerating in 2H (+56%, Auditor: PwC Related reports: 1.1H25 review: Resilient VONB uptrendwith optimistic outlook on China GrowthStrategy, Aug 22, 2025 2.Decent VONB growth across ex-Chinamarkets;buybacks to complete fasterthan expected, May 2, 20253.新业务价值增长具备韧性,新一轮回购计划提升股东回报至6%,Mar 18, 20254.Robust VONB growth in-line;newbuyback of US$1.6bn implying 6% totalS/H returns,Mar 18, 20255.FY24 preview: OPAT back to growthtrajectory; resilient VNB despite modestslowdown in 2H, Feb 24, 20256.1H24 VNB beat with margin recovery;expecttotal>US$7bn cash returns toshareholders in FY24, Aug 26, 2024 OPAT per share +12%modestly above Group’s three-year CAGR target.OPATwasatUS$7.1bn in FY25, up 7%/12% per share YoY, broadly alignedto the 9%-11% Group’s CAGR target from 2023-2025. Insurance service results comprised80% of operating profit before tax atUS$6.8bn in FY25, up 18% YoY, driven byrobust CSM release ofUS$6.2bn, up 10% YoY. Net investment results fell 5% YoYtoUS$3.1bndue to a reduction in investment return on surplus assets for further in-force book adding upto US$3bn. CSM balance climbed 15% YoY toUS$64.9bnin FY25 with notable add-ons ofUS$2.8bn variances and exchange rate movement Robust capitalto support est. 4.0% TSR in 2026E.UFSGgrew 6% or 11% pershare YoY to US$6.8bn, underpinned by higher expecteddistributable earningsfrom the in-force book (+7% YoY) and favourable operating variances that reverseda prior-year negative ofUS$127mn. Net FSG stood atUS$4.45bn, up 9%/14% pershare YoY, boosted by UFSG expansion and reduced new business investment ofUS$1.4bn (-6% YoY), which implied a deliberate shift to capital-light productsnotably in AIA China. The insurer returnedUS$4.7bn to shareholders in FY25throughUS$2.4bn dividends andUS$2.3bn buybacks. For 2026E,a newUS$1.7bn Lift TPto HK$112; Reiterate BUY.Weraise our price target to HK$112 (vs prev.HK$89) based on appraisal value approach by rolling forward forecasts to FY28E,and fine-tuning estimatesformetricswithFY26-27E VONBraisedby +3%/+3% andGroupOPAT by+3%/+3%,